Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research

Britt I Drögemöller; Galen E B Wright; Cody Lo; Tan Le; Beth Brooks; Amit P Bhavsar; Shahrad R Rassekh; Colin J D Ross; Bruce C Carleton

doi:10.1002/cpt.1483

Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research

Clin Pharmacol Ther. 2019 Aug;106(2):350-359. doi: 10.1002/cpt.1483. Epub 2019 Jun 12.

Authors

Britt I Drögemöller^{1

2}, Galen E B Wright^{2

3}, Cody Lo^{2

4}, Tan Le¹, Beth Brooks⁵, Amit P Bhavsar⁶, Shahrad R Rassekh^{2

3}, Colin J D Ross^{1

2}, Bruce C Carleton^{2

3}

Affiliations

¹ Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
² BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
³ Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
⁴ Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
⁵ Audiology and Speech Pathology Department, BC Children's Hospital, Vancouver, British Columbia, Canada.
⁶ Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

PMID: 31012503
DOI: 10.1002/cpt.1483

Abstract

Cisplatin is a highly effective chemotherapeutic. Unfortunately, its use is limited by cisplatin-induced ototoxicity (CIO). Substantial research has been performed to uncover the genetic variants associated with CIO; however, there has been a lack of consistency in the results that have been reported. This paper aims to provide an overview of the current state of CIO genomics research, delving into the shortcomings of past research, and providing recommendations for future avenues of study.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents / pharmacology
Cisplatin / pharmacology*
Humans
Ototoxicity* / etiology
Ototoxicity* / genetics
Pharmacogenetics*

Substances

Antineoplastic Agents
Cisplatin

Grants and funding

CIHR/Canada